Male (n = 19) | Female (n = 44) | |||||
---|---|---|---|---|---|---|
EMLA® or Numby® Only (n = 9) | EMLA® or Numby® + Subcutaneous Buffered Lidocaine (n = 10) | EMLA® or Numby® Only (n = 19) | EMLA® or Numby® + Subcutaneous Buffered Lidocaine (n = 25) | |||
Change in FPS-R score | Change in FPS-R score | P-value | Change in FPS-R score | Change in FPS-R score | P-value | |
All patients (n = 63) | 1.0 (0.0–2.0) | 0.5 (0.0–2.0) | 0.61 | 2.0 (2.0–5.0) | 0.0 (0.0–2.0) | 0.0004* |
Oligo-arthritis (n = 49) | 2.0 (0.0–4.0) | 0.0 (0.0–2.0) | 0.16 | 2.0 (2.0–5.0) | 0.0 (−1.0–1.0) | 0.0006* |